Simon Turton - 18 Mar 2026 Form 3 Insider Report for Biodexa Pharmaceuticals Plc (BDRX)

Reporting relationship: Director
Issuer ticker: BDRX
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 09:30:10 UTC
Source filing: View source filing
Reporting owner signature: /s/ Fiona Mary Powell, Attorney-in-Fact

Key filing fact

Simon Turton filed Form 3 for Biodexa Pharmaceuticals Plc (BDRX) on 18 Mar 2026.

Key facts

This page summarizes Simon Turton's Form 3 filing for Biodexa Pharmaceuticals Plc (BDRX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2026, 09:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001507953 Primary reporting owner

Turton Simon

Relationship: Director
Address: C/O BIODEXA PHARMACEUTICALS PLC, 1 CASPIAN POINT, CASPIAN WAY, CARDIFF, UNITED KINGDOM
Signature: /s/ Fiona Mary Powell, Attorney-in-Fact
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDRX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,765
Date: 18 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDRX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: American Depositary Shares
Underlying amount: 288
Exercise price: $475.00
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F2

Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

Footnote F3

The exercise price for this option is denominated in British pounds sterling at a price of GBP 373.936 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2703. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

SEC remarks

Exhibit 24.1 -- Power of Attorney